Manufacturer
Sun Pharmaceutical Industries Ltd.
Contents
Oxaliplatin
Indication
Adjuvant therapy in stage III colon cancer/ Metastatic colorectal cancer
Instruction
Combination therapy w/ FU/FA: 85 mg/m2 every 2 wk, given via infusion over 2-6 hr for 12 cycles. Dose may be reduced to 65 mg/m2, according to tolerability. Administered by a healthcare provider into the vein.
Drug interaction
May enhance adverse effect of live vaccines.Potentially Fatal: May diminish the therapeutic effect of vaccines. Increased risk of torsade de pointes w/ QT interval prolonging drug.
Malaysia
